Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -6 of 6 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Study Evaluating Neratinib vs Lapatinib Plus Capecitabine for ErbB2 Positive Advanced Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Approved-not yet active				18 and over				Pharmaceutical / Industry				3144A2-3003 NCT00777101


2.		A Phase I/II Study of HKI-272 in Combination With Paclitaxel in Subjects With Advanced Solid Tumors and Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				3144A1-203 NCT00445458


3.		Study Evaluating HKI-272 in Combination With Vinorelbine in Subjects With Solid Tumors and Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				3144A1-2204 NCT00706030


4.		Study Evaluating the Combination of Neratinib and Capecitabine in Solid Tumors and Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Approved-not yet active				18 and over				Pharmaceutical / Industry				3144A1-2206 NCT00741260


5.		Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Supportive care, Treatment				Active				18 to 50				Pharmaceutical / Industry				3144A1-105 NCT00708903


6.		Study Evaluating Safety and Tolerability, Solid Tumor

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				20 and over				Pharmaceutical / Industry				3144A2-1115 NCT00768469

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute